Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity
Published version of a preprint
Abstract
Although naked antigen-encoding RNA has entered clinical testing, basic knowledge on how to apply this promising novel vaccine format is still pending. By comparing different administration routes, we observed surprisingly potent antigen-specific T-cell immunity upon intranodal injection of naked antigen-encoding RNA. RNA was selectively uptaken by resident dendritic cells, propagated a T-cell attracting and stimulatory intralymphatic milieu, and led to efficient expansion of antigen-specific CD8+ as well as CD4+ T cells. By intranodal treatment of mice with repeated cycles of RNA, we achieved de novo priming of naïve T cells, which became potent cytolytic effectors capable of homing to primary and secondary lymphatic tissues as well as memory T cells. In tumor-bearing mice intralymphatic RNA vaccination elicited protective and therapeutic antitumor immune responses, resulting in a remarkable survival benefit as compared with other treatment regimens. This is the first report of strong systemic antigen-specific Th1-type immunity and cancer cure achieved with naked antigen-encoding RNA in preclinical animal models. Cancer Res; 70(22); 9031–40. ©2010 AACR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
It has been previously demonstrated that mRNA represents a potent vaccine technology (Kreiter et al, 2010; Fotin‐Mleczek et al, 2011).
“In addition, it has been previously demonstrated that mRNA represents a potent vaccine technology (Kreiter et al, 2010; Fotin‐Mleczek et al, 2011).”
From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Kreiter et al, 2010
Cites
Immunobiology of Dendritic Cells
Banchereau, J., Brière, F., Caux, C., Davoust, J. M., Lebecque, S., Liu, Y., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,612 · see citing works
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444 · see citing works
Lutz, M. B., Kukutsch, N. A., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,972 · see citing works
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062 · see citing works
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915 · see citing works
B70 antigen is a second ligand for CTLA-4 and CD28
Azuma, M., Ito, D., Yagita∥, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 910 · see citing works
Castellino, F., Huang, A. Y.-C., Altan-Bonnet, G. Y., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 847 · see citing works
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works
Self-citationInflammatory Cytokines Provide a Third Signal for Activation of Naive CD4+ and CD8+ T Cells
Curtsinger, J., Schmidt, C. S., Mondino, A., Lins, D. C., Kedl, R. M., Jenkins, M. K., & Mescher, M. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3256 · Cited by 610 · see citing works
Naik, S. H., Proietto, A. I., Wilson, N. S., Dakic, A., Schnorrer, P., Fuchsberger, M., Lahoud, M. H., O’Keeffe, M. A., Shao, Q.-X., Chen, W. F., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6592 · Cited by 551 · see citing works
Kirberg, J., Baron, A., Jakob, S. M., Rolink, A. G., Karjalainen, K., & von Boehmer, H. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.1.25 · Cited by 410 · see citing works
Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a00068 · Cited by 378 · see citing works
Cancer immunotherapy with mRNA‐transfected dendritic cells
Gilboa, E., & Vieweg, J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00139.x · Cited by 314 · see citing works
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ce501 · Cited by 261 · see citing works
Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226 · see citing works
Self-citationIncreased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals
Kreiter, S., Selmi, A., Diken, M., Sebastian, M., Osterloh, P., Schild, H., Huber, C., Türeci, Ö., & Şahin, U. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.309 · Cited by 221 · see citing works
Self-citationHernández, J., Aung, S., Redmond, W. L., & Sherman, L. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.707 · Cited by 212 · see citing works
IL-10 and TGF- induce alloreactive CD4+CD25- T cells to acquire regulatory cell function
Chen, Z.-M. (2003) · Blood · doi:10.1182/blood-2002-09-2798 · Cited by 184 · see citing works
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression
Bins, A. D., Jorritsma, A., Wolkers, M. C., Hung, C., Wu, T. ‐., Schumacher, T. N., & Haanen, J. B. A. G. (2005) · Nature Medicine · doi:10.1038/nm1264 · Cited by 178 · see citing works
Pascolo, S. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1285 · Cited by 152 · see citing works
Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines
Carralot, J.-P., Probst, J., Hoerr, I., Scheel, B., Teufel, R., Jung, G., Rammensee, H.-G., & Pascolo, S. (2004) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-004-4255-0 · Cited by 149 · see citing works
Herr, W., Linn, B., Leister, N., Wandel, E., Büschenfelde, K. M. Z., & Wölfel, T. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00019-7 · Cited by 139 · see citing works
IL-6 Increases Primed Cell Expansion and Survival
Rochman, I., Paul, W., & Ben-Sasson, S. (2005) · Journal of Immunology · doi:10.4049/jimmunol.174.8.4761 · Cited by 138 · see citing works
Tedla, N. T., Wang, H. W., McNeil, H. P., Girolamo, N. D., Hampartzoumian, T., Wakefield, D., & Lloyd, A. R. (1998) · PubMed · Cited by 109 · see citing works
Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA
Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I., Rammensee, H., Weller, M., & Pascolo, S. (2006) · European Journal of Immunology · doi:10.1002/eji.200635910 · Cited by 108 · see citing works
Tedla, N. T., Wang, H., McNeil, H. P., Girolamo, N. D., Hampartzoumian, T., Wakefield, D., & Lloyd, A. R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5663 · Cited by 95 · see citing works
Michiels, A., Tuyaerts, S., Bonehill, A., Corthals, J., Breckpot, K., Heirman, C., Van Meirvenne, S., Dullaers, M., Allard, S., Brasseur, F., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302471 · Cited by 93 · see citing works
Plasmid DNA- and messenger RNA-based anti-cancer vaccination
Weide, B., Garbe, C., Rammensee, H., & Pascolo, S. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.09.012 · Cited by 90 · see citing works
CD28, IL-2-Independent Costimulatory Pathways for CD8 T Lymphocyte Activation
Sepulveda, H., Cerwenka, A., Morgan, T., & Dutton, R. W. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1133 · Cited by 84 · see citing works
Recruitment and Activation of Natural Killer Cells In vitro by a Human Dendritic Cell Vaccine
Gustafsson, K. U., Ingelsten, M., Bergqvist, L., Nystrom, J. C., Andersson, B. A., & Karlsson‐Parra, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6494 · Cited by 78 · see citing works
Kreiter, S., Konrad, T., Sester, M., Huber, C., Türeci, Ö., & Şahin, U. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0302-7 · Cited by 51 · see citing works
Self-citationEnhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides
Smith, K. A., Tam, V. L., Wong, R. M. H., Pagarigan, R. R., Meisenburg, B. L., Joea, D. K., Liu, X., Sanders, C., Diamond, D. C., Kündig, T. M., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.038 · Cited by 33 · see citing works
Koslowski, M., Şahin, U., Huber, C., & Türeci, Ö. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl163 · Cited by 27 · see citing works
Self-citationCritical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses
Heinzerling, L., Basch, V., Maloy, K. J., Johansen, P., Senti, G., Wüthrich, B., Storni, T., & Kündig, T. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.09.018 · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works
Self-citationMutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · see citing works
Self-citationExploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 802 · see citing works
Self-citationmRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 801 · see citing works
Neoantigen vaccine: an emerging tumor immunotherapy
Miao, P., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C. J., Wu, S., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 701 · see citing works
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 680 · see citing works
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624 · see citing works
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622 · see citing works
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584 · see citing works
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579 · see citing works
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545 · see citing works
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513 · see citing works
Cell or Cell Membrane-Based Drug Delivery Systems
Tan, S., Wu, T., Zhang, D., & Zhang, Z. (2015) · Theranostics · doi:10.7150/thno.11852 · Cited by 466 · see citing works
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414 · see citing works
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385 · see citing works
Self-citationEfficient Nanovaccine Delivery in Cancer Immunotherapy
Zhu, G., Zhang, F., Ni, Q., Niu, G., & Chen, X. S. (2017) · ACS Nano · doi:10.1021/acsnano.7b00978 · Cited by 374 · see citing works
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368 · see citing works
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342 · see citing works
Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections
Senti, G., Crameri, R., Kuster, D., Johansen, P., Martinez-Gomez, J. M., Graf, N., Steiner, M., Hothorn, L. A., Grönlund, H., Tivig, C., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.026 · Cited by 271 · see citing works
Whole Tumor Antigen Vaccines: Where Are We?
Chiang, C. L.-L., Coukos, G., & Kandalaft, L. E. (2015) · Vaccines · doi:10.3390/vaccines3020344 · Cited by 270 · see citing works
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, Á., Cueto, F. J., Garasa, S., Perez‐Gracia, J. L., Sánchez-Arráez, Á., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267 · see citing works
Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 266 · see citing works
Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 257 · see citing works
Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248 · see citing works
Jewell, C. M., Bustamante-Lopez, S. C., & Irvine, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105200108 · Cited by 245 · see citing works
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234 · see citing works
Immune system targeting by biodegradable nanoparticles for cancer vaccines
Silva, J. M., Videira, M., Gaspar, R. S., Véronique Préat, A., & Florindo, H. F. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.010 · Cited by 232 · see citing works
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 234 · see citing works
An RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229 · see citing works
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228 · see citing works
A novel, disruptive vaccination technology: Self-adjuvanted RNActive <sup>®</sup> vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223 · see citing works
COVID-19: Coronavirus Vaccine Development Updates
Zhao, J., Zhao, S., Ou, J., Zhang, J., Lan, W., Guan, W., Wu, X., Yan, Y., Zhao, W., Wu, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.602256 · Cited by 225 · see citing works
RNA-Based Vaccines in Cancer Immunotherapy
McNamara, M. A., Nair, S. K., & Holl, E. K. (2015) · Journal of Immunology Research · doi:10.1155/2015/794528 · Cited by 223 · see citing works
Formulation and Delivery Technologies for mRNA Vaccines
Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 221 · see citing works
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Lint, S. V., Goyvaerts, C., Maenhout, S. K., Goethals, L., Disy, A., Benteyn, D., Pen, J. J., Bonehill, A., Heirman, C., Breckpot, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2957 · Cited by 210 · see citing works
Engineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208 · see citing works
Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208 · see citing works
Lipid-based mRNA vaccine delivery systems
Midoux, P., & Pichon, C. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.986104 · Cited by 209 · see citing works
Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C. G., Türeci, Ö., & Şahin, U. (2011) · Gene Therapy · doi:10.1038/gt.2011.17 · Cited by 192 · see citing works
Self-citationLipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., & Shen, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.019 · Cited by 187 · see citing works
RNA: The new revolution in nucleic acid vaccines
Geall, A. J., Mandl, C. W., & Ulmer, J. B. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.001 · Cited by 187 · see citing works
Ulmer, J. B., Mason, P. W., Geall, A. J., & Mandl, C. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.060 · Cited by 183 · see citing works
Clinical and immunological effects of mRNA vaccines in malignant diseases
Heine, A., Juranek, S., & Brossart, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01339-1 · Cited by 185 · see citing works
mRNA-based dendritic cell vaccines
Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., & Breckpot, K. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.957684 · Cited by 181 · see citing works
Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., & Geall, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.901308 · Cited by 177 · see citing works
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 166 · see citing works
“In addition, it has been previously demonstrated that mRNA represents a potent vaccine technology (Kreiter et al, 2010; Fotin-Mleczek et al, 2011).”
BackgroundmRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 167 · see citing works
Antigen-specific vaccines for cancer treatment
Tagliamonte, M., Petrizzo, A., Tornesello, M. L., Buonaguro, L., & Buonaguro, L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.973317 · Cited by 152 · see citing works
Programmable multistage drug delivery to lymph nodes
Schudel, A., Chapman, A. P., Yau, M., Higginson, C. J., Francis, D. M., Manspeaker, M. P., Avecilla, A. R. C., Rohner, N. A., Finn, M. G., & Thomas, S. N. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0679-4 · Cited by 153 · see citing works
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 154 · see citing works
RNA aggregates harness the danger response for potent cancer immunotherapy
Méndez‐Gómez, H. R., DeVries, A., Castillo, P., Roemeling, C. A. V., Qdaisat, S., Stover, B. D., Xie, C., Weidert, F. L., Zhao, C., Moor, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.003 · Cited by 158 · see citing works
mRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 152 · see citing works
Lazăr, D. C., Avram, M. F., Romosan, I., Cornianu, M., Tăban, S. M., & Goldiș, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i32.3583 · Cited by 144 · see citing works
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Şahin, U. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1509 · Cited by 141 · see citing works
Self-citationmRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 143 · see citing works
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139 · see citing works
Self-replicating alphavirus RNA vaccines
Ljungberg, K., & Liljeström, P. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.965690 · Cited by 137 · see citing works
Challenges and advances towards the rational design of mRNA vaccines
Pollard, C., Koker, S. D., Saelens, X., Vanham, G. L., & Grooten, J. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.002 · Cited by 134 · see citing works
Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.041 · Cited by 132 · see citing works
Towards superior dendritic-cell vaccines for cancer therapy
Saxena, M., Balan, S., Roudko, V., & Bhardwaj, N. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0250-x · Cited by 131 · see citing works
Huber, A., Dammeijer, F. F., Aerts, J. G. J. V., & Vroman, H. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02804 · Cited by 124 · see citing works
Crucial factors and emerging concepts in ultrasound-triggered drug delivery
Geers, B., Dewitte, H., Smedt, S. C. D., & Lentacker, I. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.08.014 · Cited by 124 · see citing works
The nano delivery systems and applications of mRNA
Li, M., Li, Y., Li, S., Jia, L., Wang, H., Li, M., Deng, J., Zhu, A., Ma, L., Li, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113910 · Cited by 123 · see citing works
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
Phua, K. K. L., Staats, H. F., Leong, K. W., & Nair, S. K. (2014) · Scientific Reports · doi:10.1038/srep05128 · Cited by 123 · see citing works
De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122 · see citing works
Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121 · see citing works
Kallen, K., & Theß, A. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613508729 · Cited by 120 · see citing works
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Lee, K.-W., Yam, J. W. P., & Mao, X. (2023) · Cells · doi:10.3390/cells12172147 · Cited by 124 · see citing works
Tumor vaccination using messenger RNA: prospects of a future therapy
Kreiter, S., Diken, M., Selmi, A., Türeci, Ö., & Şahin, U. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.007 · Cited by 120 · see citing works
Self-citationEngineering Strategies for Lymph Node Targeted Immune Activation
Chen, Y., Koker, S. D., & Geest, B. G. D. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00260 · Cited by 114 · see citing works
Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 113 · see citing works
Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 109 · see citing works
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 111 · see citing works
Koh, K. J., Liu, Y., Lim, S. H., Loh, X. J., Kang, L., Lim, C. Y., & Phua, K. K. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-30290-3 · Cited by 105 · see citing works
Vectors and strategies for nonviral cancer gene therapy
Pahle, J., & Walther, W. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1134480 · Cited by 104 · see citing works
Esprit, A., de Mey, W., Shahi, R. B., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 105 · see citing works
Messenger RNA vaccine based on recombinant MS2 virus‐like particles against prostate cancer
Li, J., Sun, Y., Jia, T., Zhang, R., Zhang, K., & Wang, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28482 · Cited by 103 · see citing works
Novel Platforms for the Development of a Universal Influenza Vaccine
Kumar, A., Meldgaard, T. S., & Bertholet, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00600 · Cited by 102 · see citing works
Kowalczyk, A., Doener, F., Zanzinger, K., Noth, J., Baumhof, P., Fotin-Mleczek, M., & Heidenreich, R. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.046 · Cited by 101 · see citing works
Recent developments of RNA-based vaccines in cancer immunotherapy
Faghfuri, E., Pourfarzi, F., Faghfouri, A. H., Shadbad, M. A., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1815704 · Cited by 99 · see citing works
Haghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 111 · see citing works
Immunotherapy in gastric cancer
Matsueda, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1657 · Cited by 98 · see citing works
Messenger RNA-Based Vaccines Against Infectious Diseases
Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96 · see citing works
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 99 · see citing works
The ReNAissanCe of mRNA-based cancer therapy
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95 · see citing works
Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination
Son, S., Nam, J., Zenkov, I., Ochyl, L. J., Xu, Y., Scheetz, L. M., Shi, J., Farokhzad, O. C., & Moon, J. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b03483 · Cited by 94 · see citing works
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 93 · see citing works
Lazzaro, S., Giovani, C., Mangiavacchi, S., Magini, D., Maione, D., Baudner, B. C., Geall, A. J., Gregorio, E. D., D’Oro, U., & Buonsanti, C. (2015) · Immunology · doi:10.1111/imm.12505 · Cited by 88 · see citing works
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 91 · see citing works
Selmi, A., Vascotto, F., Kautz‐Neu, K., Türeci, Ö., Şahin, U., von Stebut, E., Diken, M., & Kreiter, S. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1869-7 · Cited by 90 · see citing works
Self-citationA novel delivery platform based on Bacteriophage MS2 virus-like particles
Fu, Y., & Li, J.-M. (2015) · Virus Research · doi:10.1016/j.virusres.2015.08.022 · Cited by 68 · see citing works
DNA and mRNA vaccination against allergies
Scheiblhofer, S., Thalhamer, J., & Weiss, R. (2018) · Pediatric Allergy and Immunology · doi:10.1111/pai.12964 · Cited by 80 · see citing works
Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 79 · see citing works
FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines
Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S., Hüsemann, Y., Koslowski, M., Huber, C., Türeci, Ö., & Şahin, U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0291 · Cited by 78 · see citing works
Self-citationViral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76 · see citing works
Potential Therapeutic Applications of Rna Cap Analogs
Ziemniak, M., Strenkowska, M., Kowalska, J., & Jemielity, J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.96 · Cited by 76 · see citing works
A personalized view on cancer immunotherapy
Wayteck, L., Breckpot, K., Demeester, J., Smedt, S. C. D., & Raemdonck, K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.016 · Cited by 77 · see citing works
Cell and tissue engineering in lymph nodes for cancer immunotherapy
Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 73 · see citing works
- Authors
- Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Authors' Affiliations: 1Center for Translational Oncology and Immunology (TRON), 2Ribological, Biontech AG, and 3Department of Internal Medicine III, Division of Translational and Experimental Oncology, Johannes Gutenberg University, Mainz, Germany
- Venue
- Cancer Research
- Published
- 2010-11-14
- Volume
- 70
- Issue
- 22
- Pages
- 9031-9040
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2125677437
- Cited by
- 309
- References
- 34
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 25 · 2023: 30 · 2022: 21 · 2021: 22 · 2020: 23 · 2019: 13 · 2018: 17 · 2017: 20 · 2016: 19 · 2015: 23 · 2014: 21 · 2013: 22 · 2012: 13
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bundesministerium für Bildung und Forschung
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- intranodal injection, dendritic cells, CD8+ T cells, CD4+ T cells, Th1 response, antitumor immunity, prophylactic and therapeutic vaccination, T cell homing, memory T cells, cancer immunotherapy
- MeSH terms
- Animals, Antigens, Cytotoxicity, Immunologic, Dendritic Cells, Flow Cytometry, Immunization, Lymph Nodes, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, RNA, CD4-Positive T-Lymphocytes, Survival Analysis, Mice, Knockout, CD8-Positive T-Lymphocytes, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
